Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 324

The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.

FGF21 gene therapy as treatment for obesity and insulin resistance

Open access
Jimenez, Veronica, Jambrina, Claudia, Casana, Estefania, Sacristan, Victor, Muñoz, Sergio, Darriba, Sara, Rodó, Jordi, Mallol, Cristina, Garcia, Miquel, León, Xavier, Marcó, Sara, Ribera, Albert, Elias, Ivet, Casellas, Alba, Grass, Ignasi, Elias, Gemma, Ferré, Tura, Motas, Sandra, Franckhauser, Sylvie, Mulero, Francisca, Navarro, Marc, Haurigot, Virginia, Ruberte, Jesus, Bosch, Fatima·2018·EMBO Molecular Medicine

Abstract

Prevalence of type 2 diabetes (T2D) and obesity is increasing worldwide. Currently available therapies are not suited for all patients in the heterogeneous obese/T2D population, hence the need for novel treatments. Fibroblast growth factor 21 (FGF21) is considered a promising therapeutic agent for T2D/obesity. Native FGF21 has, however, poor pharmacokinetic properties, making gene therapy an attractive strategy to achieve sustained circulating levels of this protein. Here, adeno-associated viral vectors (AAV) were used to genetically engineer liver, adipose tissue, or skeletal muscle to secrete FGF21. Treatment of animals under long-term high-fat diet feeding or of ob/ob mice resulted in marked reductions in body weight, adipose tissue hypertrophy and inflammation, hepatic steatosis, inflammation and fibrosis, and insulin resistance for > 1 year. This therapeutic effect was achieved in the absence of side effects despite continuously elevated serum FGF21. Furthermore, FGF21 overproduction in healthy animals fed a standard diet prevented the increase in weight and insulin resistance associated with aging. Our study underscores the potential of FGF21 gene therapy to treat obesity, insulin resistance, and T2D.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.201708791

Cites

97 of 97 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 97 references

Cited by

See all 324

Metadata

Authors
Jimenez, V., Jambrina, C., Casana, E., Sacristan, V., Muñoz, S., Darriba, S., Rodó, J., Mallol, C., Garcia, M., León, X., Marcó, S., Ribera, A., Elias, I., Casellas, A., Grass, I., Elias, G., Ferré, T., Motas, S., Franckhauser, S., Mulero, F., Navarro, M., Haurigot, V., Ruberte, J., & Bosch, F.
Venue
EMBO Molecular Medicine
Published
2018-07-09
Volume
10
Issue
8
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W2881519211
Cited by
324
References
97
FWCI
9.73
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: FGF21 gene therapy as treatment for obesity and insulin resistance. https://app.cochat.ai/papers/10.15252/emmm.201708791
The paper
Jimenez, V., Jambrina, C., Casana, E., Sacristan, V., Muñoz, S., Darriba, S., Rodó, J., Mallol, C., Garcia, M., León, X., Marcó, S., Ribera, A., Elias, I., Casellas, A., Grass, I., Elias, G., Ferré, T., Motas, S., Franckhauser, S., . . . Bosch, F. (2018). FGF21 gene therapy as treatment for obesity and insulin resistance. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201708791

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.